David Pinato: Immunotherapy might become a novel standard of care in intermediate-stage HCC

David Pinato, Director of Developmental Cancer Therapeutics at Imperial College London, shared on LinkedIn:

“Immunotherapy might become a novel standard of care in intermediate-stage HCC.

PETAL is the first study to focus on mechanisms of synergy between TACE and PD-1 inhibition at Imperial College London.”

Proceed to the article.
Source: David Pinato/LinkedIn